Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05005728
Title XmAb20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements Yes
Sponsors Xencor, Inc.

castration-resistant prostate carcinoma



Olaparib + XmAb20717

Cabazitaxel + Carboplatin + XmAb20717

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST